4552 — JCR Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- ¥64bn
- ¥109bn
- ¥40bn
Announces Research Collaboration, Option And License Agreement With Alexion To Develop A Therapy Using J-Brain Cargo For Neurodegenerative Disease
Table: Jcr Pharmaceuticals -2022/23 group forecast
Announces Achievement Of Preclinical Proof-Of-Concept Milestone Using J-Brain Cargo Technology For Lysosomal Storage Disorder In Gene Therapy Collaboration With Takeda
Table: Jcr Pharmaceuticals - 9-MTH group results
Brief: Jcr Pharmaceuticals Co Ltd Medipal Holdings And Jcr Pharmaceuticals Agree On Granting Of Exclusive Negotiation Rights For Global Commercialization Targeting Four Ultra-Rare Diseases And Conclude A Licensing Contract For Commercialization Of A Fucosidosis Therapeutic
To Initiate Development Of New Drug Candidate For Fucosidosis
Table: Jcr Pharmaceuticals - 6-MTH group results
Notice Of Selection As Meti Project For Establishing Biopharmaceutical Manufacturing Sites To Strengthen Vaccine Production
Established JCR Europe B.V. As New Subsidiary For Conducting Clinical Development Activities
Update On Application For Manufacturing And Marketing Approval Of Jr-141 For Treatment Of Mps Ii (Hunter Syndrome) In Brazil
To Spend 6.2 Billion Yen To Take 20.48% Stake In Mycenax Biotech Inc
Table: Jcr Pharmaceuticals -Q1 group results
Table: Jcr Pharmaceuticals -2021/22 group results
Table: Jcr Pharmaceuticals -2021/22 parent results
Table: Jcr Pharmaceuticals - 9-MTH group results
Table: Jcr Pharmaceuticals - 6-MTH group results
Table: Jcr Pharmaceuticals -2021/22 group forecast
Table: Jcr Pharmaceuticals -Q1 group results
S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt official